Tipsheet
What matters at India’s listed companies
M&A · Medical Equipment · Micro cap

Shree Pacetronix's joint MD just put ₹2.56 cr of his own money into the stock

Akash Sethi's stake jumped from 8.76% to 13.51% after acquiring 1,78,000 shares in an off-market deal worth ~4.7% of the ₹54 crore company.

2 earlier stories on Shree Pacetronix Ltd.
Mkt cap₹50.85 cr
P/E16.17×
ROE5.44%
Debt / eq.0.37
₹2.56 cr Estimated value of the promoter's acquisition, ~4.7% of the nano-cap's market capitalization.

What's new

  • Joint MD Akash Sethi acquired 1,78,000 shares via off-market transfer from Bio Pace Technology INC.
  • His voting stake increased from 8.76% to 13.51% of the cardiac-device maker's equity.
  • He already holds warrants convertible into another 1.50 lakh shares.

Why this matters

For a company worth ₹54 crore, deploying ₹2.56 crore of personal capital is a significant commitment from a senior insider. It directly increases the joint MD's alignment with minority shareholders and removes a block from the share register.

What we're watching

  • Whether Sethi converts his outstanding warrants for another 1.50 lakh shares.
  • Any further stakebuilding by Sethi or other insiders.
  • Bio Pace Technology's remaining position after this off-market transfer.

The full read

Akash Sethi is the joint managing director of Shree Pacetronix, a ₹54 crore cardiac-device maker. He just bought 1,78,000 shares from Bio Pace Technology in an off-market deal valued at about ₹2.56 crore. That's nearly 4.7% of the company's entire market value deployed in one transaction. His direct stake jumped from 8.76% to 13.51%. A big move. He already holds warrants convertible into 1.50 lakh more shares, so his potential exposure is even higher. The seller, Bio Pace Technology, has cleanly exited a position. For a promoter already running the company, this is a clear, voluntary allocation of personal capital into the stock. The open question is whether this is a one-off or the beginning of a larger accumulation.

Questions answered

Who sold the shares and at what price?
Bio Pace Technology INC sold 1,78,000 shares to the promoter in an off-market deal. The filing does not disclose the price, but the analyst rationale estimates the value at approximately ₹2.56 crore.
How does this affect the company's shareholding structure?
The transaction materially alters the cap table: Sethi's direct voting stake jumped 475 basis points to 13.51%. For a nano-cap firm, such a shift in insider ownership is a notable structural change.
What is the full extent of Sethi's potential exposure?
His direct holding is now 13.51%. He also holds warrants convertible into 1.50 lakh additional shares, which would further increase his stake upon exercise.
Why is a **₹2.56 crore** deal for a **₹54 crore** company significant?
The acquisition represents roughly 4.7% of the entire market capitalization. For a promoter to deploy that scale of personal capital in a single block trade is a strong confidence signal from an insider who knows the business intimately.
Mentioned: Akash Sethi · Bio Pace Technology INC · ₹2.56 cr transaction value
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

  1. 10 Jun 2026 · 5:22 PM IST Shree Pacetronix's joint MD just put ₹2.56 cr of his own money into the stock
  2. 16d ago Shree Pacetronix's profit surges 300% on leaner balance sheet
  3. 16d ago Shree Pacetronix checks its annual boxes